Bandow Julia Elisabeth, Brötz Heike, Leichert Lars Ingo Ole, Labischinski Harald, Hecker Michael
Institut für Mikrobiologie, Ernst-Moritz-Arndt-Universität, 17489 Greifswald, Germany.
Antimicrob Agents Chemother. 2003 Mar;47(3):948-55. doi: 10.1128/AAC.47.3.948-955.2003.
We have used proteomic technology to elucidate the complex cellular responses of Bacillus subtilis to antimicrobial compounds belonging to classical and emerging antibiotic classes. We established on two-dimensional gels a comprehensive database of cytoplasmic proteins with pIs covering a range of 4 to 7 that were synthesized during treatment with antibiotics or agents known to cause generalized cell damage. Although each antibiotic showed an individual protein expression profile, overlaps in the expression of marker proteins reflected similarities in molecular drug mechanisms, suggesting that novel compounds with unknown mechanisms of action may be classified. Indeed, one such substance, a structurally novel protein synthesis inhibitor (BAY 50-2369), could be classified as a peptidyltransferase inhibitor. These results suggest that this technique gives new insights into the bacterial response toward classical antibiotics and hints at modes of action of novel compounds. Such a method should prove useful in the process of antibiotic drug discovery.
我们利用蛋白质组学技术阐明了枯草芽孢杆菌对属于传统和新型抗生素类别的抗菌化合物的复杂细胞反应。我们在二维凝胶上建立了一个细胞质蛋白质的综合数据库,这些蛋白质的等电点范围为4至7,是在抗生素或已知会导致广泛细胞损伤的药物处理过程中合成的。尽管每种抗生素都显示出独特的蛋白质表达谱,但标记蛋白表达的重叠反映了分子药物作用机制的相似性,这表明可以对作用机制未知的新型化合物进行分类。事实上,一种这样的物质,一种结构新颖的蛋白质合成抑制剂(BAY 50 - 2369),可被归类为肽基转移酶抑制剂。这些结果表明,该技术为细菌对传统抗生素的反应提供了新的见解,并暗示了新型化合物的作用模式。这种方法在抗生素药物发现过程中应该会被证明是有用的。